Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$226.64 USD

226.64
643,701

+3.23 (1.45%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $226.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down

An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.

Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Sheraz Mian headshot

Top Research Reports for NVIDIA, Amazon.com & UnitedHealth

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Amazon.com, Inc. (AMZN) and UnitedHealth Group Incorporated (UNH).

Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification

Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

Boston Scientific (BSX) DBS Programming Software Gets CE Mark

Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.

Here's Why You Should Retain Inari Medical (NARI) for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Medtronic (MDT) Shares Positive Data for MiniMed 780G System

Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.

Best Momentum Stock to Buy for June 24th

SCS, BKNIY and RMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24, 2024.

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds

IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.

Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics

Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.

Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.